OA06.05 A phase I study to assess safety, pharmacokinetics and pharmacodynamics of a topical multipurpose prevention insert containing tenofovir alafenamide fumarate and elvitegravir dosed vaginallyOral Abstract SessionClinical trial results
OA07.01 SMS reminders did not improve PrEP adherence in a randomized controlled trial among young Kenyan womenOral Abstract SessionBehavioural and social science research
OA07.02 “I just decided to stop:” Understanding PrEP discontinuation among individuals initiating PrEP in HIV care centers in Kenya and its implications for a public health approach to preventionOral Abstract SessionBehavioural and social science research
OA07.03 Limited Knowledge of, Interest in, and Eligibility for Event-Driven PrEP among MSM in Two Samples in the United StatesOral Abstract SessionBehavioural and social science research
OA07.04 I'm taking PrEP for myself and not for people: PrEP disclosures influence adherence journeys for adolescent girls and young women in South AfricaOral Abstract SessionBehavioural and social science research
OA07.05LB High initiation and persistence on pre-exposure prophylaxis (PrEP) in HIV-uninfected pregnant women in Cape Town, South AfricaOral Abstract SessionImplementation science, including structural interventions, PrEP & VMMC
OA08.01 Antibody isotype switching as a mechanism to counter HIV neutralization escapeOral Abstract SessionHumoral immunity
OA08.02 Vaccination induces maturation of diverse unmutated VRC01-class precursors to HIV-1 broadly neutralizing antibodies in an Ig-humanized mouse modelOral Abstract SessionBroadly neutralizing antibodies
OA08.03 Combinations of scFv of HIV bNAbs demonstrate high breadth and potency against a multiclade panel of virusesOral Abstract SessionBroadly neutralizing antibodies
OA08.04 Active tuberculosis co-infection enhances HIV-1 specific humoral immunityOral Abstract SessionHumoral immunity
seek-warrow-warrow-eseek-e31 - 40 of 444 items